cerrar
Tagged with ALS

Sweden Pharma R&D Snapshot
Over EUR 1 billion was spent in Sweden on pharmaceutical R&D in 2015, a similar level to spending seen in Italy and Denmark. Made with…

Taiwan Innovation Snapshot
As part of its 'Asia Silicon Valley Development Plan', Taiwan has designated a special focus to each of its regions. The Taiwanese government is…

Hospital IT Solutions in Spain: At a Disruption Point
With cost pressures mounting, Spain is increasingly turning towards digital solutions to maintain the high levels of care provided by its healthcare…

dMed: More Than Just a CRO
Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx…

AI in Clinical Trials: Improving Efficiency, Reducing Costs
Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will…

Basyouni Abuseif – Country President and CPO Head, Novartis…
Basyouni Abuseif, country president and CPO Head at Novartis Egypt, explains how the Swiss company has taken over the leadership position in the…

Mohsen Shalaby – President, Nerhadou International, Egypt
Dr Mohsen Shalaby, President of Nerhadou, explains how he has built Egypt’s leading mineral supplement and nutraceuticals company from scratch…

Bertrand Sohier – VP & General Manager Business and…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research…

Aurora Berra – General Manager, Sobi Spain and Portugal
Aurora Berra, general manager of Sobi Spain and Portugal, highlights her key priorities and the opportunities and challenges inherent in the…

Mohamed Swilam – Country Manager, Roche Egypt
Mohamed Swilam, country manager of Roche Egypt, explains how ensuring access to medicine in Egypt is not only related to pricing challenges, but also…

Jin Hyoung Kang – President, Cancer Study Group, South…
Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from…

Rethinking Clinical Trials in Rare Diseases
Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here